Characterization of a Newly Discovered Non-Coding Variant in the EPO Gene Identified in Two Unrelated Italian Pedigrees With Erythrocytosis [0.03%]
两个独立的意大利红细胞增多症家系中新发现的EPO基因非编码变异位点的表征研究
Barbara Mora,Valentina Bellani,Daniela Pietra et al.
Barbara Mora et al.
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent [0.03%]
TP53突变和循环原始细胞≥20%是接受一线维纳妥拉联合低甲基化药物治疗的加速期/急变期骨髓增殖性肿瘤患者生存的主要决定因素
Naseema Gangat,Momna Warraich,Sudhesh Kumar et al.
Naseema Gangat et al.
Survival outcome among 82 Mayo Clinic patients with blast/accelerated phase myeloproliferative neoplasm (MPN-BP/AP). Keywords: ...
G-CSF for Mobilizing CD34+ Cells in Individuals With SCD: A Word of Caution [0.03%]
有关G-CSF用于动员SCD患者CD34+细胞的一则警示性说明
Akshay Sharma,Allistair Abraham,Monica Bhatia et al.
Akshay Sharma et al.
Excess Risk of Monoclonal Gammopathy in Patients With Gaucher Disease [0.03%]
Gaucher病患者的单克隆丙球蛋白血症风险增加
Majdolen Istaiti,Katie Thoren,Dickran Kazandjian et al.
Majdolen Istaiti et al.
MACOP-B in Adult Langerhans Cell Histiocytosis Confirms Durable Organ Responses at an Updated Long-Term Follow-Up [0.03%]
更新的长期随访结果证明，成人朗格汉斯细胞组织细胞增生症患者在MACOP-B方案治疗后有持续性的器官反应
Alessandro Broccoli,Enrico Derenzini,Lisa Argnani et al.
Alessandro Broccoli et al.
Acquired Hemolytic Anemia Is Associated With Higher Risk of Symptomatic Gallstone Disease [0.03%]
获得性溶血性贫血与有症状胆石症的风险增加有关
Anders Blach Naamansen,Stinne Tranekær,Frederik Christensen et al.
Anders Blach Naamansen et al.
Matthew P Davidsohn,Divij Verma,Yiyu Zou et al.
Matthew P Davidsohn et al.
Magnetic Resonance Imaging as a Complementary Diagnostic Tool for Aplastic Anemia [0.03%]
磁共振成像作为再生障碍性贫血的辅助诊断工具
Jeanette Walter,Peter Isfort,Susanne Isfort et al.
Jeanette Walter et al.
Case Reports
American journal of hematology. 2026 Feb 14. DOI:10.1002/ajh.70236 2026
Differential Prognosis and Transplant Strategies in CBF-AML With RUNX1::RUNX1T1 Versus CBFβ::MYH11 Fusions [0.03%]
RUNX1-RUNX1T1与CBFβ-MYH11融合在CBF-AML中的预后及移植策略的区别
Jingtao Huang,Huihong Huang,Yunxiang Zhang et al.
Jingtao Huang et al.
Core binding factor acute myeloid leukemia (CBF-AML) is defined by t(8;21) or inv. (16), which give rise to the RUNX1::RUNX1T1 and CBFβ::MYH11 fusion genes, respectively. CBF-AML is a favorable-risk AML subtype, yet differences in mutation...
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia [0.03%]
新诊断的急性髓系白血病患者连续周期使用28天维奈克拉片的耐受性和疗效评估
Michael K Jones,Jesse Sanchez,Megan Connor et al.
Michael K Jones et al.
The standard of care for newly-diagnosed unfit patients with acute myeloid leukemia (AML) is venetoclax (VEN) with azacitidine (AZA). In the phase 3 trial, before remission, AZA was given with 28 days of VEN. This regimen is myelosuppressiv...